Immunovant (NASDAQ: IMVT) net income
Immunovant reported a net loss of $505.6m for fiscal 2026; in fiscal 2025 it reported a net loss of $413.8m. Earnings per share were −$2.77.
Immunovant's best year of the last 8 was fiscal 2019. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2026 | −$505.6m | — | — | −$2.77 |
| 2025 | −$413.8m | — | — | −$2.73 |
| 2024 | −$259.3m | — | — | −$1.88 |
| 2023 | −$211.0m | — | — | −$1.71 |
| 2022 | −$156.7m | — | — | −$1.43 |
| 2021 | −$107.4m | — | — | −$1.22 |
| 2020 | −$66.4m | — | — | — |
| 2019 | −$28.6m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immunovant net income compared with its sector
By net income for its latest fiscal year, Immunovant ranks 473rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 471st | Oscar Health | −$443.2m | −3.8% |
| 472nd | Dyne Therapeutics | −$446.2m | — |
| 473rd | Immunovant | −$505.6m | — |
| 474th | Denali Therapeutics | −$512.5m | — |
| 475th | Integra Lifesciences | −$516.5m | −31.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Immunovant
- How much did Immunovant earn in fiscal 2026?
- Immunovant reported a net loss of $505.6m for fiscal 2026. In fiscal 2025 it reported a net loss of $413.8m.
- What are the earnings per share of Immunovant?
- They were −$2.77 in fiscal 2026, compared with −$2.73 in fiscal 2025.
- Where does Immunovant rank in its sector by net income?
- It ranks 473rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Immunovant come from?
- From the annual report (Form 10-K) that Immunovant files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immunovant files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Immunovant: the Immunovant page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.